Chemours Shares Plunge 16.8% Following Disappointing Earnings Report
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Feb 20 2026
0mins
Should l Buy CC?
Source: Fool
- Disappointing Earnings: Chemours reported a 2.2% revenue decline in Q4, aligning with Wall Street expectations, but adjusted EPS fell 46% to $0.05, missing estimates by $0.02, leading to a significant stock price drop.
- Cautious Future Outlook: The company forecasts 3% to 5% revenue growth for 2026, projecting revenues between $5.98 billion and $6.10 billion, which, while in line with analyst consensus, failed to excite the market, putting pressure on the stock.
- EBITDA Growth Potential: Adjusted EBITDA is expected to range from $800 million to $900 million in 2026, marking a 14.6% increase at the midpoint over 2025's $742 million, indicating potential for improved profitability in the short term.
- High-Growth Product Opportunity: Chemours' Opteon low-carbon refrigerants grew 56% last year, boosting the Thermal Solutions segment by 13%, and if other cyclical segments recover, Opteon could become a key driver of future growth for the company.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy CC?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on CC
Wall Street analysts forecast CC stock price to fall
7 Analyst Rating
5 Buy
2 Hold
0 Sell
Moderate Buy
Current: 17.420
Low
13.00
Averages
16.14
High
19.00
Current: 17.420
Low
13.00
Averages
16.14
High
19.00
About CC
The Chemours Company provides industrial and specialty chemical products for markets, including coatings, plastics, refrigeration and air conditioning, transportation, semiconductor and advanced electronics, general industrial, and oil and gas. The Company’s segments include Titanium Technologies, Thermal & Specialized Solutions and Advanced Performance Materials. The Titanium Technologies segment is a provider of titanium dioxide pigment, a premium white pigment used to deliver whiteness, brightness, opacity and protection in various applications. The Thermal & Specialized Solutions segment is a provider of refrigerants, thermal management solutions, propellants, blowing agents, and specialty solvents. The Advanced Performance Materials segment is a provider of high-end polymers and advanced materials. Its flagship products include brands such as Opteon, Freon, Ti-Pure, Nafion, Teflon, Viton, and Krytox. The Company serves over 2,700 customers in approximately 110 countries.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Chemours Under Investigation for Securities Fraud Claims
- Investigation Launched: Pomerantz LLP is investigating Chemours and its executives for potential securities fraud and other unlawful business practices, aiming to protect investor rights and possibly leading to legal liabilities for the company.
- Financial Impact: Chemours reported on February 19, 2026, that its 2025 EBITDA was negatively impacted by a one-time inventory charge in its Advanced Performance Materials segment, indicating short-term cyclical headwinds in the market.
- Stock Price Volatility: Following the earnings report, Chemours' stock price fell by $3.37, or 16.51%, closing at $17.04 per share on February 20, 2026, reflecting market concerns over the company's financial health.
- Legal Context: Pomerantz LLP, a prominent securities class action law firm with over 85 years of experience, focuses on advocating for victims of securities fraud and corporate misconduct, which could significantly impact Chemours' future litigation outcomes.
See More
Chemours Prices $700 Million Offering of 7.875% Senior Notes
- Increased Offering Size: Chemours announced an increase in its offering of 7.875% senior notes from the initially planned $600 million to $700 million, reflecting strong market confidence in its financing needs, with the offering expected to close on March 12, 2026.
- Interest Rate and Maturity: The new notes will mature in 2034 with an annual interest rate of 7.875%, paying interest semi-annually starting September 15, 2026, which will provide Chemours with stable cash inflows to support its operations.
- Clear Use of Proceeds: Chemours intends to use the net proceeds from this offering to redeem its outstanding 5.375% senior notes due 2027 and partially redeem its 5.750% senior notes due 2028, aiming to reduce financial costs and optimize its capital structure, thereby enhancing financial flexibility.
- Compliance and Market Positioning: The notes are being offered only to persons reasonably believed to be qualified institutional buyers in reliance on Rule 144A under the Securities Act of 1933, indicating Chemours' compliance in the capital markets and its appeal to institutional investors.
See More
Investigation into Chemours Company for Securities Fraud
- Investigation Launched: Pomerantz LLP is investigating whether Chemours Company and its executives have engaged in securities fraud or other unlawful business practices, aiming to protect investor rights and potentially initiate a class action lawsuit.
- Financial Impact: Chemours reported on February 19, 2026, that its 2025 EBITDA was negatively impacted by a one-time inventory charge in its Advanced Performance Materials segment, indicating short-term cyclical headwinds in the market.
- Stock Price Volatility: Following the earnings report, Chemours's stock price fell by $3.37, or 16.51%, closing at $17.04 per share on February 20, 2026, reflecting market concerns over the company's financial health.
- Legal Context: Pomerantz LLP, a prominent firm in securities and antitrust class litigation with over 85 years of experience, is dedicated to fighting for the rights of victims of securities fraud and corporate misconduct, which could significantly impact Chemours's legal outlook.
See More
Chemours Plans $600M Senior Notes Offering to Fund Debt Redemption
- Debt Restructuring Plan: Chemours intends to offer $600 million in new senior notes due 2034, which is expected to optimize its capital structure and reduce financial costs.
- Clear Use of Proceeds: The net proceeds from this bond issuance will be used to redeem the outstanding 5.375% senior notes due 2027 and to repurchase a portion of the 5.750% senior notes due 2028, thereby improving the company's debt maturity profile.
- Subsidiary Guarantee: The new notes will be guaranteed by a subsidiary of Chemours, enhancing the credit rating of the bonds and reducing investor risk.
- Stable Market Reaction: Despite Chemours' stock dipping 0.11% to $18 in pre-market trading, the company remains focused on its adjusted EBITDA target of $800 million to $900 million for 2026, indicating its commitment to future cash flow and deleveraging efforts.
See More
Chemours Plans to Offer $600 Million in New Senior Notes
- Bond Offering Plan: Chemours intends to offer $600 million in new senior notes due in 2034, aiming to optimize its capital structure and reduce financing costs.
- Debt Redemption Strategy: The net proceeds from this offering will be used to redeem its 5.375% senior notes maturing in 2027 and to repurchase a portion of its 5.750% senior notes due in 2028, thereby alleviating future interest burdens.
- Compliance Requirements: The new notes are being offered only to investors reasonably believed to be qualified institutional buyers, in compliance with Rule 144A under the Securities Act of 1933, ensuring the offering's regulatory adherence.
- Market Risk Advisory: Chemours cautions investors that the success of the bond offering is subject to market conditions and other uncertainties, which could significantly impact the company's financial position.
See More
The Upcoming AI Investment Opportunity Lies with Chemical and Cooling System Manufacturers
Hyperscaler Investment: Hyperscalers are investing hundreds of billions of dollars each year to secure a competitive edge in the AI arms race.
Market Impact: This significant spending has led to fluctuations in the stock prices of chip makers, memory companies, and data center builders over recent years.
See More
Chemours Under Investigation for Securities Fraud Claims
- Investigation Launched: Pomerantz LLP is investigating Chemours and its executives for potential securities fraud and other unlawful business practices, aiming to protect investor rights and possibly leading to legal liabilities for the company.
- Financial Impact: Chemours reported on February 19, 2026, that its 2025 EBITDA was negatively impacted by a one-time inventory charge in its Advanced Performance Materials segment, indicating short-term cyclical headwinds in the market.
- Stock Price Volatility: Following the earnings report, Chemours' stock price fell by $3.37, or 16.51%, closing at $17.04 per share on February 20, 2026, reflecting market concerns over the company's financial health.
- Legal Context: Pomerantz LLP, a prominent securities class action law firm with over 85 years of experience, focuses on advocating for victims of securities fraud and corporate misconduct, which could significantly impact Chemours' future litigation outcomes.
See More
Chemours Prices $700 Million Offering of 7.875% Senior Notes
- Increased Offering Size: Chemours announced an increase in its offering of 7.875% senior notes from the initially planned $600 million to $700 million, reflecting strong market confidence in its financing needs, with the offering expected to close on March 12, 2026.
- Interest Rate and Maturity: The new notes will mature in 2034 with an annual interest rate of 7.875%, paying interest semi-annually starting September 15, 2026, which will provide Chemours with stable cash inflows to support its operations.
- Clear Use of Proceeds: Chemours intends to use the net proceeds from this offering to redeem its outstanding 5.375% senior notes due 2027 and partially redeem its 5.750% senior notes due 2028, aiming to reduce financial costs and optimize its capital structure, thereby enhancing financial flexibility.
- Compliance and Market Positioning: The notes are being offered only to persons reasonably believed to be qualified institutional buyers in reliance on Rule 144A under the Securities Act of 1933, indicating Chemours' compliance in the capital markets and its appeal to institutional investors.
See More
Investigation into Chemours Company for Securities Fraud
- Investigation Launched: Pomerantz LLP is investigating whether Chemours Company and its executives have engaged in securities fraud or other unlawful business practices, aiming to protect investor rights and potentially initiate a class action lawsuit.
- Financial Impact: Chemours reported on February 19, 2026, that its 2025 EBITDA was negatively impacted by a one-time inventory charge in its Advanced Performance Materials segment, indicating short-term cyclical headwinds in the market.
- Stock Price Volatility: Following the earnings report, Chemours's stock price fell by $3.37, or 16.51%, closing at $17.04 per share on February 20, 2026, reflecting market concerns over the company's financial health.
- Legal Context: Pomerantz LLP, a prominent firm in securities and antitrust class litigation with over 85 years of experience, is dedicated to fighting for the rights of victims of securities fraud and corporate misconduct, which could significantly impact Chemours's legal outlook.
See More
Chemours Plans $600M Senior Notes Offering to Fund Debt Redemption
- Debt Restructuring Plan: Chemours intends to offer $600 million in new senior notes due 2034, which is expected to optimize its capital structure and reduce financial costs.
- Clear Use of Proceeds: The net proceeds from this bond issuance will be used to redeem the outstanding 5.375% senior notes due 2027 and to repurchase a portion of the 5.750% senior notes due 2028, thereby improving the company's debt maturity profile.
- Subsidiary Guarantee: The new notes will be guaranteed by a subsidiary of Chemours, enhancing the credit rating of the bonds and reducing investor risk.
- Stable Market Reaction: Despite Chemours' stock dipping 0.11% to $18 in pre-market trading, the company remains focused on its adjusted EBITDA target of $800 million to $900 million for 2026, indicating its commitment to future cash flow and deleveraging efforts.
See More
Chemours Plans to Offer $600 Million in New Senior Notes
- Bond Offering Plan: Chemours intends to offer $600 million in new senior notes due in 2034, aiming to optimize its capital structure and reduce financing costs.
- Debt Redemption Strategy: The net proceeds from this offering will be used to redeem its 5.375% senior notes maturing in 2027 and to repurchase a portion of its 5.750% senior notes due in 2028, thereby alleviating future interest burdens.
- Compliance Requirements: The new notes are being offered only to investors reasonably believed to be qualified institutional buyers, in compliance with Rule 144A under the Securities Act of 1933, ensuring the offering's regulatory adherence.
- Market Risk Advisory: Chemours cautions investors that the success of the bond offering is subject to market conditions and other uncertainties, which could significantly impact the company's financial position.
See More
The Upcoming AI Investment Opportunity Lies with Chemical and Cooling System Manufacturers
Hyperscaler Investment: Hyperscalers are investing hundreds of billions of dollars each year to secure a competitive edge in the AI arms race.
Market Impact: This significant spending has led to fluctuations in the stock prices of chip makers, memory companies, and data center builders over recent years.
See More
